Approval · Notice of Compliance 26979 · 2021
BEOVU: Notice of Compliance 26979
Issued November 4, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26979
- Date
- November 4, 2021
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BEOVU | Not yet assigned | — |
Medicinal ingredients
- BROLUCIZUMAB 120 MG per ML
- BROLUCIZUMAB 6 MG per VIAL